FDA Clearance Tracker · P160048-S016
Eversense® E3 Continuous Glucose Monitoring System
Last checked: Nov 20, 2026Latest source record: Feb 10, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Feb 10, 2022
Approved
Time to decision
498 days
Received Sep 30, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P160048-S016
- Device name
- Eversense® E3 Continuous Glucose Monitoring System
- Applicant
- Senseonics, Incorporated
- Applicant location
- Germantown, MD
- Received
- Sep 30, 2020
- Decided
- Feb 10, 2022
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P160048
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the Eversense® E3 Continuous Glucose Monitoring System for expanding the indications for use and modifying the sensor design to allow use for up to 180 days.
Source documents
Other decisions for Senseonics, Incorporated
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K241335 · Decided Sep 16, 2024 · 126 days after receipt
Device type: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA) · Laboratory Medicine & Pathology
4 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.